Regulus Therapeutics Inc (RGLS NASDAQ) stock market data APIs
$8.168
-0.06(-0.7%)
as of June 24, 2025
Try our APIs with
free plan!
Regulus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.
Prev. Close
8.168
Open
8.109
High
8.2384
Low
7.9976
52 wk Range
0.8301-8.345
Market Cap
565 M
Shares Outstanding
69 234 K
Revenue
5 000 K
EPS
-0.15
Beta
0.368
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regulus Therapeutics Inc data using free add-ons & libraries
Get Regulus Therapeutics Inc Fundamental Data
Regulus Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 000 K
- EBITDA: -51 401 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.265
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regulus Therapeutics Inc News
New
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the sh...
Novartis completes acquisition of Regulus Therapeutics and initiates Nasdaq delisting
Novartis AG (SIX:NOVN) has completed its acquisition of Regulus Therapeutics Inc . (NASDAQ:RGLS), according to a press release statement filed with the Securities and Exchange Commission. The transa...
Novartis completes acquisition of Regulus Therapeutics
Novartis Pharma AG Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquis...
Novartis announces expiration of Regulus Therapeutics tender offer
Novartis Pharma AG Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wh...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
